Evidence map›Paper›PMID 28839086›Full record

ArticleAntimicrobial agents and chemotherapy2017

Erratum for Peloquin et al., "Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis".

C A Peloquin, G E Velásquez, L Lecca, R I Calderón, J Coit, M Milstein, E Osso, J Jimenez, K Tintaya, E Sanchez Garavito and 3 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

C A PeloquinUniversity of Florida College of Pharmacy and Emerging Pathogens Institute, Gainesville, Florida, USA.
G E VelásquezDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.
L LeccaDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
R I CalderónSocios En Salud, Lima, Peru.
J CoitDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.
M MilsteinDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.
E OssoDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.
J JimenezSocios En Salud, Lima, Peru.
K TintayaSocios En Salud, Lima, Peru.
E Sanchez GaravitoHospital Nacional Sergio Bernales, Lima, Peru.
D Vargas VasquezHospital Nacional Hipólito Unanue, Lima, Peru.
C D MitnickDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
G DaviesInstitutes of Infection and Global Health and Translational Medicine, University of Liverpool, Liverpool, United Kingdom.

Funding

Randomized Trial of High-Dose Rifampin in Patients with New Smear-Positive TBU01AI091429 · NIAID · HARVARD MEDICAL SCHOOL · PI DAVIES, GERAINT, MITNICK, CAROLE D. · 2011 to 2013
$8.5M
NIAID NIH HHS L30 AI120170NIAID NIH HHS U01 AI091429
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID28839086
PMCPMC5571311

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.